A common description of antibiotic action aims to classify them between “bactericidal” or “bacteriostatic”. Although these phenomena have robust in vitro foundations, the clinical translation of these concepts is sometimes difficult to ascertain. This controversial topic has important conceptual ramifications to treat severe infections. Today, we will discuss this topic with an expert in field.

Watch the video version here: https://youtu.be/3z4BItBrzbk

• The definitions of “cidal” vs “static” antibiotics
• The clinical applicability of the above terms in terms of antibiotic choice and syndromatic approaches
• antibiotic choices and the controversy between bactericidal and bacteriostatic antibiotics.

• Brad Spellberg, MD. Chief Medical Officer at the Los Angeles General Medical Center

• ASM and IDSA launch the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) in 2026
• Watch this session on YouTube

This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal.

Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.

Oversight and guidance for performing antibiotic susceptibility testing can be bewildering. There is an alphabet soup of agencies and bodies involved: FDA, CLSI, and USCAST, to name a few here in the US. How does the Food and Drug Administration, which has regulatory authority over AST, work with a nimble group like the Clinical Laboratory Standards Institute?

• Romney Humphries, Ph.D., D(ABMM), M(ASCP)
• Patricia Simner, Ph.D., D(ABMM)

• Major updates to FDA-recognized Clinical and Laboratory Standards Institute breakpoints are a win for the fight against antimicrobial resistance
• Join ASM for up to 50% off the publication fees when you publish in JCM or any of the ASM journals.
• Attend ASM Microbe

This episode of Editors in Conversation is brought to you by the Journal of Clinical Microbiology and hosted by JCM Editor in Chief, Alex McAdam and Dr. Elli Theel. JCM is available at https://jcm.asm.org and on https://twitter.com/JClinMicro.

Visit journals.asm.org/journal/jcm to read articles and/or submit a manuscript.

Follow JCM on Twitter/𝕏 via @JClinMicro

In the last decade, there have been major changes in the approach of the treatment of pneumonia, in particular, with the availability of new diagnostic tools. Additionally, new drugs have been approved for the treatment of pneumonia. We discuss the approach to the management of pneumonia with a person who has spent most of his professional career working on this topic.

• Definitions and nomenclature of pneumonia and evolution of these terms
• Changes in the diagnosis of pneumonia
• Ttherapeutic changes and future approaches for the treatment of pneumonia.

• Daniel M Musher, M.D.

• ASM and IDSA launch the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) in 2026

This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal.

Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.